Back to search
FDAFDA · Food and drugs·Recall number D-1501-2016

buPROPion Hydrochloride Extended-Release Tablets, USP (XL), 300mg, 500-count bottle, Rx only, Manufactured by: Cadila Healthcare Ltd., Ahmedabad, India For BluePoint Laboratories, NDC 68001-264-03

Published September 21, 2016 · Recall initiated: August 4, 2016

Summary

FDA records drug Class III recall D-1501-2016, published September 21, 2016 and initiated August 4, 2016. Recalling firm: Amerisource Health Services; Status: Terminated; Reported quantity: 2626 bottles; Lot: Lot #: MS1509, Exp 12/17. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed dissolution specifications - the out of specification result for dissolution was identified during 3 month stability testing.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Amerisource Health Services
Distributor
Nationwide and Puerto Rico
Lot
Lot #: MS1509, Exp 12/17
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was buPROPion Hydrochloride Extended-Release Tablets, USP (XL), 300mg, 500-count bottle, Rx only, Manufactured by: Cadila Healthcare Ltd., Ahmedabad, India For BluePoint Laboratories, NDC 68001-264-03 recalled?

Yes. FDA published recall D-1501-2016 on September 21, 2016. Reported hazard: Failed dissolution specifications - the out of specification result for dissolution was identified during 3 month stability testing.

What should I do if I have this product?

Voluntary: Firm initiated · Letter